You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Merck
Medtronic
AstraZeneca
McKinsey

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

TAUVID Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Tauvid, and when can generic versions of Tauvid launch?

Tauvid is a drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this drug.

This drug has seventeen patent family members in eight countries.

The generic ingredient in TAUVID is flortaucipir f-18. One supplier is listed for this compound. Additional details are available on the flortaucipir f-18 profile page.

US ANDA Litigation and Generic Entry Outlook for Tauvid

Tauvid will be eligible for patent challenges on May 28, 2024. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 19, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for TAUVID
International Patents:17
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 2
DailyMed Link:TAUVID at DailyMed
Drug patent expirations by year for TAUVID
Generic Entry Opportunity Date for TAUVID
Generic Entry Date for TAUVID*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TAUVID

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Avid RadiopharmaceuticalsPhase 1
Avid RadiopharmaceuticalsEarly Phase 1

See all TAUVID clinical trials

US Patents and Regulatory Information for TAUVID

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-001 May 28, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Avid Radiopharms Inc TAUVID flortaucipir f-18 SOLUTION;INTRAVENOUS 212123-002 May 28, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Johnson and Johnson
McKinsey
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.